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Background: Souroubea sympetala Gilg. is a neotropical vine native to Central America,
investigated as part of a targeted study of the plant family Marcgraviaceae. Our previous
research showed that extract of S. sympetala leaf and small branch extract had anxiolytic
effects in animals and acts as an agonist for the GABAA receptor at the benzodiazepine
binding site. To date, the potential effects of S. sympetala and its constituents on
reconsolidation have not been assessed. Reconsolidation, the process by which
formed memories are rendered labile and susceptible to change, may offer a window of
opportunity for pharmacological manipulation of learned fear. Here, we assessed the
effects of S. sympetala crude extract and isolated phytochemicals (orally administered) on
the reconsolidation of conditioned fear. In addition, we explored whether betulin (BE), a
closely related molecule to betulinic acid (BA, an active principal component of S.
sympetala), has effects on reconsolidation of learned fear and whether BE may
synergize with BA to enhance attenuation of learned fear.
Method: Male Sprague–Dawley rats received six 1.0-mA continuous foot shocks
(contextual training). Twenty-four hours later, rats were re-exposed to the context (but
in the absence of foot shocks). Immediately following memory retrieval (recall), rats
received oral administration of S. sympetala extract at various doses (8–75 mg/kg) or
diazepam (1 mg/kg). In separate experiments, we compared the effects of BA (2 mg/kg),
BE (2 mg/kg), and BA + BE (2 mg/kg BA + 2 mg/kg BE). The freezing response was
assessed either 24 h later (day 3) or 5 days later (day 7). Effects of phytochemicals on fear
expression were also explored using the elevated plus maze paradigm.
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Results: S. sympetala leaf extract signiﬁcantly attenuated the reconsolidation of
contextual fear at the 25- and 75-mg/kg doses, but not at the 8-mg/kg dose.
Furthermore, BA + BE, but not BA or BE alone, attenuated the reconsolidation of
learned fear and exerted an anxiolytic-like effect on fear expression.
Keywords: reconsolidation, fear memory, Souroubea sympetala, Sin Susto, betulinic acid, betulin

sympetala leaf extract and betulinic acid reduced stressorinduced cortisol secretion in rainbow trout and canines
(Mullally et al., 2017; Masic et al., 2018). Evidence also suggests
S. sympetala and BA may exert their effects on fear learning and
expression by agonizing the benzodiazepine (BZD) binding site
of the GABAA receptor (Mullally et al., 2014). This is in line with
evidence suggesting that anxiolytic botanicals frequently possess
agonistic qualities for the GABAergic system (Awad et al., 2009).
In contrast to traditional GABAA BZD receptor agonists such
as diazepam, our previous research with S. sympetala leaf extract
indicated that there were no withdrawal effects in rodents (Cayer,
2011). Thus, the plant might effectively modulate learned fear
and/or anxiety with limited negative side effects typically
associated with GABAA BZD agonists. S. sympetala extracts
and its combinations with another BA-producing plant have
been safe in 30-day feeding trials at elevated doses with dogs
(Villalobos et al., 2014; Liu et al., 2017).
In addition to its experimentally demonstrated activity as an
anxiolytic, S. sympetala may also possess memory-altering
qualities that prove useful for the treatment of other human
mood disorders. Reconsolidation blockade, a technique for
pharmacologically altering formed memories, may provide an
avenue for developing novel treatment approaches for alleviating
traumatic memories which are resistant to extinction. Evidence
suggests that following retrieval, memories may return to a labile
state in which they are susceptible to manipulation (Nader et al.,
2000). During this period (the reconsolidation window),
pharmacological disruption of memory re-stabilization can
potentially diminish conditioned fear responses (and thus their
expression). This technique has been used in preclinical research
to help identify potential therapeutic targets (Debiec and
LeDoux, 2006; Lin et al., 2006; Pitman et al., 2011; Murkar
et al., 2017). Some, such as the b-adrenergic antagonist
propranolol, xenon (which blocks NMDA receptors), and
gastrin-releasing peptide (homologue of the amphibian peptide
bombesin), show promise of attenuating learned fear when
administered during the reconsolidation window in rodents
(Debiec and LeDoux, 2006; Meloni et al., 2014; Murkar et al.,
2017). Although it has only been sparsely tested in humans, there
is some evidence from translational studies to suggest that the
blockade of reconsolidation may have practical applications.
Propranolol, for example, reduces physiologic responses to
traumatic imagery in sufferers of PTSD when administered
post-recall (Brunet et al., 2008). However, ﬁndings are mixed,
and subsequent follow-up studies have failed to replicate this
effect (Spring et al., 2015). Thus, new targeted approaches are
required to help identify viable treatments to attenuate fear
memory reconsolidation in humans.

INTRODUCTION
Fear-based disorders such as anxiety and posttraumatic stress
disorder (PTSD) make up a signiﬁcant portion of all diagnosed
psychiatric conditions. A recent large-scale study found that
among college students worldwide, major depression and
anxious disorders are the most prevalent—with generalized
anxiety and panic disorders constituting a combined 23.6% of
all psychiatric conditions (with a 12-month prevalence rate for
all mental conditions among the sampled population of over
30%; Auerbach et al., 2018). Despite that they are relatively
commonplace, existing treatments for fear-based disorders are
extremely limited. Pharmacological interventions for generalized
anxiety are largely limited to benzodiazepines, while
serotonergic–noradrenergic reuptake inhibitors (SNRIs) are
also in use for panic disorder.
Moreover, although PTSD affects a large percentage of
individuals following exposure to trauma (Van Ameringen
et al., 2008), there are no speciﬁc pharmacological treatments
targeting PTSD. Rather, the current treatments instead aim to
treat the comorbid symptoms of anxiety and/or depression
(Morina et al., 2014). It is also of interest to note that more
than half of individuals with fear-based disorders seek alternative
medicine (approaches to the treatment of illness which fall
outside of the scope of standard medical care; Kessler et al.,
2001). However, only 20% of those in the same study sought the
guidance of a health care practitioner (i.e., a large percentage selfmedicate; Kessler et al., 2001). As a result, it is clear that new
pharmacotherapies are needed to speciﬁcally address PTSD (as
well as other fear-based disorders).
In an attempt to discover alternate treatment strategies, efforts
have been underway to explore plant-based remedies. Indeed,
some plant extracts have been shown to exert anxiolytic-like
effects (Arnason et al., 1981; Bourbonnais-Spear et al., 2006;
Bourbonnais-Spear et al., 2007; Galdino et al., 2012; Bahi et al.,
2014), and in particular we found that a Canadian genotype,
Sedum roseum (L.) Scop. (syn. Rhodiola rosea Murkar et al.,
2016), may be useful for the development of novel therapeutic
interventions for human disorders based in fear memory. As part
of our collaborative research to ﬁnd new anxiolytics, we targeted
the poorly studied family of neotropical vines, the
Marcgraviaceae, in Central America. In preclinical tests
modeling anxiety-like symptoms in animals, extract of one of
these vines, Souroubea sympetala Gilg. (Marcgraviaceae; Sin
Susto), has shown promise as an effective anxiolytic. Betulinic
acid (BA; the most prominent triterpenoid constituent of the
plant) is one of the active molecules responsible for this effect (see
Figure 1; Mullally et al., 2011; Puniani et al., 2015). Both S.
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FIGURE 1 | Chemical structure of (1) betulinic acid and (2) betulin.

Since some phytochemicals have been shown to affect
reconsolidation and expression of learned fear (Stern et al.,
2012; Murkar et al., 2016), phytotherapy may offer a novel
approach to reconsolidation blockade as a treatment paradigm
for fear-based disorders. Phytochemicals that affect
consolidation and/or extinction of fear memory, as well as
compounds acting through GABA that attenuate fear
expression, may have memory-altering properties that
generalize to other processes such as reconsolidation (although
reconsolidation and extinction are thought to be distinct
processes at the cellular and molecular level; Suzuki et al.,
2004). Research has demonstrated that reconsolidation of
learned fear can be altered by GABAergic neurotransmission
in rodents following memory recall (Bustos et al., 2009). As
possible GABAA BZD receptor agonists, S. sympetala extract and
its active components might therefore be of use to the
development of novel treatment approaches for fear-based
disorders by affecting fear memory.
Here, we aimed to determine whether S. sympetala extract
and its primary active component BA could block the
reconsolidation of conditioned fear. In addition to BA and S.
sympetala leaf and small branch extract (SIN), we also explored
the effects of a more abundant but closely related molecule—
betulin (BE)—on reconsolidation of conditioned fear, and also a
combination of the two (BA + BE) to determine whether the
effects of BA are altered by the addition of BE. Previous work
has shown that amyrins of similar chemical structure synergize
with BA to enhance its effects (Cayer, 2011). We hypothesized
that a similar effect may be observed with BE, given its very
similar structure to BA (BA is structurally identical to BE,
except for the exchange of the alcohol group with a carboxylic
acid group). We also hypothesized that the leaf and small
branch extract and BA would signiﬁcantly attenuate
reconsolidation of conditioned fear in a dose-dependent
manner and that the effects of BA would be ampliﬁed by coadministration with BE.
Finally, in order to test for more general effects of isolated
compounds from SIN on fear expression and anxiety-like
behavior, we explored the effects of isolated phytochemicals
BE, BA, and a combination of the two using the elevated plus
maze paradigm.

Frontiers in Pharmacology | www.frontiersin.org

METHODS
Animals
Male Sprague–Dawley rats (Charles River Laboratories
International, Inc.; 180–200 g on arrival) were doubly housed
and maintained on a 12-h light/dark cycle (lights on at 0700
hours). Temperature was maintained at 23°C and relative
humidity at 37%. Throughout the duration of the study,
animals had free access to food and water. All experiments
were conducted in accordance with the guidelines established
by the Canadian Council on Animal Care and approved by the
University of Ottawa Animal Care Committee.

Drugs and Injections
Animals were habituated to administration of oral sweetened
condensed milk (vehicle) 1 week prior to the beginning of the
experiment. Since evidence suggests S. sympetala extract may act
as a GABAA BZD receptor agonist, diazepam (Sandoz, Canada)
was used as a positive control. Rats were randomly assigned to
one of the treatment groups used throughout the experiments.
Drug groups among all experiments consisted of 1) S. sympetala
leaf and small branch extract (SIN, 8–75 mg/kg); 2) diazepam
(positive control, 1 mg/kg); 3) BA (2 mg/kg); 4) BE (2 mg/kg); 5)
BA + BE (2 mg/kg BA + 2 mg/kg BE); and 6) vehicle.

Plant Extract, Isolated Phytochemicals,
and Analysis
S. sympetala Gilg. leaves and small branches were originally
collected in Tortuguero, Costa Rica, and propagated at a
Universidad Nacional ﬁeld in Sarapiqui. Samples were dried
overnight in a commercial plant drier at 35°C. A voucher
specimen was identiﬁed by two of us (MOR and PS) and
deposited in the JVR herbarium, (see Supplementary Figure 1)
Universidad Nacional Costa Rica (voucher no. 13231, in
Supplementary Data). S. sympetala is an accepted name on the
plant.list.org and tropicos.org. Plant material of S. sympetala was
ground with a Wiley Mill (2-mm mesh size). Samples were
incubated with shaking in 1:20 (weight/volume) ethyl acetate
(EtOAc) for 12–15 h at room temperature. The solvent was
ﬁltered (Whatman no. 1) and the ﬁlter cake re-extracted twice
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minimum baseline freezing level of 40% during recall (assessed
on day 2) were removed from the analyses.

with half as much EtOAc (1:10 and 1:5). The total solvent from the
three extractions were combined for an exhaustive extraction. The
solvent was removed via rotary evaporation with a Yamato Rotary
Evaporator RE50 (Yamato Scientiﬁc, Japan) at 40°C, lyophilized
(Super Modulyo, Thermo Electron, USA), and stored in opaque
glass vials at 4°C. Analysis of the plant was undertaken using a
validated high-performance liquid chromatography–mass
spectrometry (HPLC-MS) method (Liu et al, 2019) which shows
chromatograms for the analysis. The extract contained a mean
(SE) of betulinic acid of 6.8 mg (0.2). Isolation, puriﬁcation, and
spectroscopic identiﬁcation of betulinic acid and betulin have been
described previously (Puniani et al., 2015) and was found to be
greater than 95% pure by HPLC-MS.

Experimental Procedure
Experiment 1: Effects of Plant Extracts on
Reconsolidation Blockade, Short Term
Animals were exposed to six consecutive 1-s foot shocks over the
course of 11 min. Contextual conditioning was used (pairing of
foot shock with the conditioning chamber). Twenty-four hours
later, animals were re-exposed to the context in which they
received the foot shock (conditioning chamber) for 5 min and
freezing (total time spent in complete immobility) was measured
(day 2, recall). Cage placement and assignment to drug treatment
groups was randomized/counterbalanced.
Immediately after the 5-min recall session on day 2, animals
were administered drugs in one of ﬁve treatment groups: 8 mg/kg
plant extract (low dose), 25 mg/kg plant extract (medium dose),
75 mg/kg plant extract (high dose), vehicle, and 1 mg/kg
diazepam (positive control). Twenty-four hours later (day 3),
animals were re-exposed to the conditioning chamber and
freezing was measured over the course of 10 min in blocks of
0–5 and 6–10 min. The timeline of procedures for experiment 1
is illustrated in Figure 2.

Contextual Fear Conditioning
The conditioning chambers (Coulbourn Instruments) measured
31 × 25 × 30 cm. The front and back walls were made of clear
acrylic, and the two sidewalls and top made of stainless steel. The
ﬂoor comprised 16 stainless steel bars (4-mm diameter spaced
1.4 cm apart) connected to Coulbourn precision-regulated
animal shockers, which delivered scrambled foot shock (1.0
mA). Animals (N = 7–10/group) were randomly distributed
into treatment groups. Subjects that failed to achieve a

FIGURE 2 | S. sympetala extracts attenuated the freezing response. 25 mg/kg SIN (approximate BA content 0.37 mmol/kg) and 75 mg/kg SIN (approximate BA
content 1.12 mmol/kg), but not 8 mg/kg SIN (approximate BA content 0.12 mmol/kg), attenuated freezing on day 3 when administered immediately post-recall.
* indicates p < 0.05.
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min. The timeline of procedures for experiment 3 is illustrated in
Figure 4.

Experiment 2: Long-Term Effects on Reconsolidation
Blockade
The same training procedures as experiment 1 were utilized to
test for long-term effects of plant compounds on fear memory
reconsolidation blockade. Immediately after the 5-min recall
session on day 2, animals were administered drugs in one of
ﬁve treatment groups: 8 mg/kg plant extract (low dose), 25 mg/kg
plant extract (medium dose), 75 mg/kg plant extract (high dose),
vehicle, and 1 mg/kg diazepam (positive control). Five days later
(day 7), animals were re-exposed to the conditioning chamber
and freezing was measured over the course of 10 min in blocks of
0–5 and 6–10 min. The timeline of procedures for experiment 2
is illustrated in Figure 3.

Experiment 4: Long-Term Effects of Plant Extracts
on Reconsolidation Blockade
The same training procedures as experiment 1 were utilized to
test for long-term effects of plant compounds on fear memory
reconsolidation blockade. Immediately after the 5-min recall
session on day 2, animals were administered drugs in one of four
treatment groups: 2 mg/kg BE, 2 mg/kg BA, 2 mg/kg BE + 2 mg/
kg BA, or vehicle. Five days later (day 7), animals were reexposed to the conditioning chamber and freezing was
measured over the course of 10 min in blocks of 0–5 and 6–
10 min. The timeline of procedures for experiment 4 is
illustrated in Figure 5.

Experiment 3: Short-Term Effects of Plant Extracts
on Reconsolidation Blockade

Experiment 5: Attenuation of the Fear Response
Requires Reactivation of the Fearful Memory Trace

The same training procedures as experiment 1 were utilized to
test for short-term effects of isolated plant compounds on fear
memory reconsolidation blockade. Immediately after the 5-min
recall session on day 2, animals were administered drugs in one
of four treatment groups: 2 mg/kg BE, 2 mg/kg BA, 2 mg/kg BE +
2 mg/kg BA, or vehicle. Twenty-four hours later (day 3), animals
were re-exposed to the conditioning chamber and freezing was
measured over the course of 10 min in blocks of 0–5 and 6–10

In order to determine whether the effects were dependent upon
memory trace reactivation, an experiment was performed using
identical procedures to experiment 1 and experiment 3. In this
experiment, however, animals were not re-exposed to the fearful
stimulus on day 2. The timeline of procedures for experiment 5 is
illustrated in Figure 6.

FIGURE 3 | S. sympetala extract administered immediately following recall did not attenuate freezing on day 7.
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FIGURE 4 | Isolated phytochemicals betulinic Acid (BA) 2 mg/kg (4.38 mmol/kg) and betulin (BE) 2 mg/kg (4.52 mmol/kg) attenuated reconsolidation of conditioned
fear when co-administered, but not alone. The combined dose of BA + BE more closely resembles S. sympetala extract. * indicates p < 0.05.

Experiment 6: Elevated Plus Maze

test revealed the assumption of equality of error variances was
violated at 6–10 min (p < 0.05). There was also a signiﬁcant time
by group interaction effect [F(4,41) = 4.485, p < 0.05].
Post hoc analyses further revealed that animals who received
medium and high doses of plant extract immediately following
memory recall on day 2 displayed signiﬁcantly less freezing than
vehicle-treated animals on day 3 at 0–5 min (p < 0.05; see
Figure 2). Animals that received high-dose plant extract or
diazepam immediately following recall on day 2 also displayed
signiﬁcantly less freezing than vehicle-treated animals on day 3 at
6–10 min (p < 0.05).

The elevated plus maze (EPM), a paradigm used to characterize
anxiety-like behavior, was conducted in accordance with methods
as described by Cayer et al. (2013). The maze consisted of two
open arms (50 × 10 cm) and two perpendicular arms enclosed by
high walls (40 cm tall). The maze was placed 50 cm above the
ground. Percentage of time spent in the open arms and number
of unprotected head dips were measured.

Statistical Analyses
All statistical analyses were conducted using IBM Statistics
Package for the Social Sciences® (SPSS) 20. Data was analyzed
using mixed-measures ANOVA, in which drug treatment was
the between -groups variable and time was the within-groups
variable. Greenhouse–Geisser correction was applied where the
assumption of sphericity is violated. Follow-up comparisons of
signiﬁcant main effects and interaction effects were conducted
using Bonferroni-corrected t-tests, or corrected post hoc tests
where the assumption of homogeneity of variance was violated.

Experiment 2
The mixed-measures ANOVA revealed no signiﬁcant main
effects or interaction effects [F(4,41) = 0.291, p > 0.05] (see
Figure 3).

Experiment 3
The mixed-measures ANOVA revealed a signiﬁcant time by
group interaction effect [F(4,40) = 5.227, p < 0.01] and a
signiﬁcant main effect of group [F(4,40) = 3.505, p < 0.05].
Levene’s test revealed the assumption of equality of error
variances was violated [F(4,40) = 4.549, p < 0.05]. Games–
Howell corrected post hoc analysis revealed that rodents that
had received BA 2 mg/kg + BE 2 mg/kg exhibited signiﬁcantly
less freezing than vehicle-treated animals (p < 0.05) at the 6- to

RESULTS
Experiment 1
The mixed-measures ANOVA revealed a signiﬁcant main effect of
treatment on levels of freezing [F(4,41) = 5.523, p < 0.01]. Levene’s
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FIGURE 5 | Isolated phytochemicals 2 mg/kg (4.52 mmol/kg) BE and 2 mg/kg (4.38 mmol/kg) BA did not attenuate freezing on day 7.

10-min interval (see Figure 4). No other groups signiﬁcantly
differed from vehicle at either the 0- to 5- or 5- to 10-min interval
(all p > 0.05).

0.01]. Levene’s test indicated the assumption of equality of error
variances was violated (p > 0.05). Follow-up analyses indicated
that rats treated with BA + BE (p < 0.05) and diazepam (p < 0.05)
had signiﬁcantly more unprotected head dips than vehicletreated animals (see Figure 8). No other groups signiﬁcantly
differed from vehicle.

Experiment 4
The mixed-measures ANOVA revealed no signiﬁcant main effects
or interaction effects, [F(4,40) = 0.952, p > 0.05] (see Figure 5).

DISCUSSION

Experiment 5
The mixed-measures ANOVA revealed no signiﬁcant main effects
or interaction effects, [F(2,27) = 0.062, p > 0.05] (see Figure 6).

Our ﬁndings suggest that S. sympetala leaf and small branch
extract is effective in modulating reconsolidation of learned fear
and fear expression. In experiment 1, 25 mg/kg SIN and 75 mg/
kg SIN (but not 8 mg/kg SIN) effectively attenuated the learned
fear response as measured on day 3 when administered
immediately post-recall. This suggests that S. sympetala plant
extract may have therapeutic potential for modulating
reconsolidation of learned fear. However, there was no
signiﬁcant effect of SIN at day 7 (long-term testing).
Our ﬁndings also demonstrated signiﬁcant effects of 2 mg/kg
BA + 2 mg/kg BE both on reconsolidation of learned fear
responses and on fear expression in the EPM paradigm.
However, similarly to what we observed with SIN, BA + BE
was effective at attenuating reconsolidation of learned fear in the
short term, but not the long term. Although it is possible the
effects of SIN and BA + BE are not permanent, this would be

Experiment 6
A one-way ANOVA revealed a signiﬁcant main effect of
treatment group in the EPM paradigm on percentage of time
spent in the open arms of the maze [F(4,40) = 3.297, p < 0.05].
Levene’s test indicated the assumption of equality of error
variances was not violated (p > 0.05). Follow-up analyses
indicated that rats treated with diazepam (p < 0.05) and a
combination of BA + BE (2 mg/kg each; p < 0.05) spent
signiﬁcantly more time in the open arms of the EPM than
vehicle-treated animals (see Figure 7). No other treatment
groups signiﬁcantly differed from vehicle.
One-way ANOVA also revealed a signiﬁcant treatment effect
on the number of unprotected head dips [F(4,40) = 5.084, p <
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FIGURE 6 | SIN 75 mg/kg (approximate BA content 1.12 mmol/kg) and a combined dose of 2 mg/kg (4.52 mmol/kg) BE + 2mg/kg (4.38 mmol/kg) BA did not
produce attenuation of the learned fear response when administered in the absence of re-exposure to the fearful stimulus.

ﬂoor effect is responsible for this observation in both cases since
mean freezing levels at day 7 in both long-term experiments
were much lower overall for all groups in both of our long-term
experiments. A reduction in freezing levels with the CER
paradigm after 7 days is unfortunately not unusual. Future
work should therefore aim to determine whether the effects of
SIN and its active principal components persist in the long term
using measures that are less sensitive to drift over time and ﬂoor
effects (e.g., fear-potentiated startle, which produces robust
measurable effects even after longer periods). It would also be
advantageous for future studies to include testing at a longer
interval (i.e., day 10 or 15).
In addition to highlighting that SIN and BA + BE may
effectively modulate learned fear and fear expression, our
ﬁndings also suggest that BE may indeed synergize the effects
of BA—since both BA and BE alone were ineffective at
attenuating the learned fear response or fear expression, but a
combined dose yielded signiﬁcant effects on both reconsolidation
of learned fear (in experiments 3) and fear expression (in
experiment 6). The results of these experiments are in partial
agreement with previous ﬁndings. For example, previously, our
group showed that BA exerted an anxiolytic effect when
administered alone (Puniani et al., 2015).
However, our prior work suggests that while BA may be an
active principal of S. sympetala extracts, it is likely not the only

FIGURE 7 | Rodents treated with 2 mg/kg (4.52 mmol/kg) BE + 2 mg/kg
(4.38 mmol/kg) BA, as well as 1 mg/kg (3.51 mmol/kg) diazepam, exhibited
signiﬁcantly more time in the open arms of the maze than rodents treated
with vehicle. * indicates p < 0.05.

inconsistent with previous work suggesting that memories
targeted by reconsolidation blockade are not prone to
reinstatement (Nader et al., 2000; Bustos et al., 2009; Meloni
et al., 2014; Murkar et al., 2017). Rather, we anticipate that a
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(Cayer, 2011) while maintaining fulsome therapeutic effects on
fear expression. Whether S. sympetala extracts produce
withdrawal effects in humans after chronic administration,
however, has yet to be explored. It will be a necessary and
important step for future studies to determine whether—
as suggested by its use in traditional native medicine—the
effects of S. sympetala extracts translate well to studies with
human participants.

DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
FIGURE 8 | Rodents treated with 2 mg/kg (4.52 mmol/kg) BE + 2 mg/kg
(4.38 mmol/kg) BA, as well as 1 mg/kg (3.51 mmol/kg) diazepam, exhibited
signiﬁcantly more unprotected head dips than rodents treated with vehicle.
* indicates p < 0.05.

ETHICS STATEMENT
The animal study was reviewed by the University of Ottawa
Animal Care Committee. All experiments were conducted in
accordance with the guidelines established by the Canadian
Council on Animal Care and approved by the University of
Ottawa Animal Care Committee.

active component. Thus, our combined BA + BE group may be
the closest representation of the extract and the original leaf/
small branch decoction Sin Susto, which contains both BA and a
host of likely bioactive molecules.
Our ﬁndings here highlight the potential therapeutic beneﬁt
of S. sympetala, betulinic acid (BA), and betulin (BE, as a possible
synergist) for mediation of learned fear and fear expression.
However, further research is necessary to explore the nature of
triterpenoid synergism. Future studies may beneﬁt from a more
extensive dose–response characterization of BA effects to
determine more precisely the effective dose range of BA. In
addition, although we have observed robust effects on behavior
and memory, our experiments did not probe the central
mechanisms mediating the effects of these compounds. Future
studies should therefore aim to elucidate the central mechanisms
by which S. sympetala extracts might exert their effects. Since
evidence suggests BA and S. sympetala extract may act as
GABAA BZD receptor agonists (Mullally et al., 2014), it would
be an important future step to determine whether the effects of
orally administered SIN and/or BA + BE are mediated centrally
and whether these effects can be blocked by a selective GABAA
BZD binding site antagonist (such as ﬂumazenil) as well as with
site-speciﬁc microinjection of those antagonists at brain regions
where GABAergic transmission is known to play a role in
learned fear (e.g., the basolateral complex of the amygdala;
Duvarci and Pare, 2014).
Overall, our data suggests that S. sympetala extracts and
isolated phytochemicals may prove useful as pharmacological
targets for the development of new and more effective treatments
for human fear-based disorders such as PTSD. Furthermore, in
contrast to the current mainline treatments for anxiety, some
experiments suggest that BA produced no changes in weight gain
or locomotor activity, as well as no withdrawal effects on food
intake, fecal output, and a variety of light-phase and dark-phase
behaviors including scratching, grooming, resting, and exploring
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